Font Size

Profile

Menu Style

Cpanel

Novartis buys Glaxo’s cancer arm for $16 billion

 

Novartis will focus more on cancer, GlaxoSmithKline on vaccines and Eli Lilly & Co on animal health as the drug makers announced a series of deals for a total of as much as $28.5 billion on Tuesday. The transactions, as well as a plan to form a consumer health joint venture with Glaxo, are part of an overhaul of the pharmaceutical industry spurred by the loss of sales as best-selling medicines lose patent protection. Pfizer, the world's biggest drug maker, sold its infant nutrition business to Nestle for $11.9 billion in 2012, and then last year spun off its animal health unit. Novartis agreed to buy cancer drugs for as much as $16 billion while selling most of the company's vaccines division to Glaxo for $7.1 billion and its animal health unit to Lilly for $5.4 billion. 

 http://news.ifeng.com/gundong/detail_2014_04/23/35967578_0.shtml

 

On the subject of us

At Asian Agribusiness Consulting our mission is the promotion and development of agribusiness across Asia. We provide specialist research and consulting services for our clients who have intentions of ratcheting up their presence in Asia be they start-ups companies to blue-chip companies.

Read more

Top Events